Regarding MDM2/X inhibitors, a clinical phase III trial using combination with idasanutlin (RG7388) and cytarabine, which is a chemotherapeutic agent, is being performed in relapse/refractory acute myeloid leukemia patients [111]. The gene discussed is MDM2; the disease is acute myeloid leukemia.